Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.60
Bid: 111.00
Ask: 111.40
Change: -0.40 (-0.36%)
Spread: 0.40 (0.36%)
Open: 111.00
High: 111.80
Low: 110.40
Prev. Close: 111.00
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Syncona confident after Q1 market volatility

Tue, 16th Aug 2022 10:06

(Sharecast News) - Healthcare investor Syncona reported net assets of £1.33bn at the end of its first quarter on Tuesday, or 197.9p per share, up from £1.31bn and 194.4p per share at the end of March.

The FTSE 250 company said that made for a net asset value return of 1.8% in the three months ended 30 June, driven by the positive impact of foreign exchange across the portfolio and capital pool.

Its life science portfolio was valued at £561.8m, up from £524.9m, with a return of -0.2% in the quarter.

The share prices of Syncona's listed holdings were still being negatively impacted by market volatility, although the board said it remained "confident" in the fundamentals of its companies.

It added that the portfolio remained funded to deliver on upcoming clinical milestones in the 2023 financial year, with £38m deployed in the period and a capital base of £768.7m as at 30 June, down from £784.9m at the end of March.

The company said that capital base provided it with a strategic advantage, as it looked to fund "exciting" new opportunities while supporting its current portfolio.

"We are pleased with the continued progress across the Syncona portfolio during the quarter, with our companies delivering on a number of operational and clinical milestones," said Martin Murphy, chair and chief executive officer at Syncona Investment Management.

"Our strategic capital base remains a key competitive advantage, enabling us to continue to fund our companies through the current market conditions, with £38m of capital deployed in the quarter, and strongly positioning us to take advantage of exciting opportunities to found new Syncona companies."

Murphy said Syncona was founded with a long-term vision and approach to leverage its experience in managing life science companies through all market cycles.

"We are confident that we can navigate the current environment to deliver strong risk-adjusted returns for our shareholders and fulfil our purpose to extend and enhance human life."

At 0940 BST, shares in Syncona were down 0.2% at 199.2p.

Reporting by Josh White at Sharecast.com.

More News
2 May 2018 10:32

Syncona's Blue Earth Signs Licence For Prostate Cancer Imaging Agent

LONDON (Alliance News) - Life science focused investment trust Syncona Ltd said Wednesday its portfolio company Blue Earth Diagnostics has signed an exclusive licence for a radio-hybride prostate

Read more
4 Apr 2018 08:21

Syncona's Nightstar 2017 Loss Widens On Research And Development Costs

LONDON (Alliance News) - Healthcare-focused investment company Syncona Ltd said on Wednesday that itsportfolio company Nightstar Therapeutics PLC reported a widened loss in as

Read more
9 Mar 2018 08:43

Syncona Revises Investment Management Arrangement To Save Costs

LONDON (Alliance News) - Syncona Ltd said on Tuesday it has revised its investment management agreement with BACIT UK Ltd in order to reduce costs for has

Read more
6 Mar 2018 10:38

WINNERS & LOSERS SUMMARY: Investors Lose Appetite For Just Eat

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Smurfit up it

Read more
6 Mar 2018 09:20

Syncona And Arix Bioscience Notes Potential US IPO For Autolus (ALLIPO)

LONDON (Alliance News) - FTSE 250-listed healthcare investment company Syncona Ltd said on Tuesday its portfolio company Autolus Ltd, has filed a confidential submission of a

Read more
5 Mar 2018 13:07

Syncona's Nightstar Begins NSR-REP1 Trial And Appoints New Director

LONDON (Alliance News) - Healthcare-focused investment company Syncona Ltd said on Monday that portfolio company Nightstar Therapeutics PLC has initiated a STAR Phase Three to

Read more
23 Jan 2017 17:09

Syncona Takes Advice On FCA's Pooled Investment Marketing Restrictions

Read more
29 Feb 2012 14:19

Small caps round-up: Imaginatik, Braveheart, Healthcare Locums...

Imaginatik has signed a new annual contract with a leading provider of healthcare services and medical research in the US. The contract has an initial start-up phase worth $0.12m in the current calendar year, followed by an ongoing annual contract worth $0.15m a year, with Imaginatik supplying it

Read more
29 Feb 2012 06:57

Wednesday newspaper round-up: Cove, Vodafone, HSBC

HSBC has admitted for the first time it may face criminal charges that could see it hit with "significant" penalties stemming from a US investigation into alleged money-laundering by Britain's biggest bank. The bank is being investigated over possible violations of the US Bank Secrecy Act. HSBC also

Read more
24 Feb 2012 06:56

Friday newspaper round-up: Greece, Oil, BoE

Germany's ruling parties are to introduce a resolution in parliament blocking any further boost to the EU's bail-out machinery, vastly complicating Greece's rescue package and risking a major clash with the International Monetary Fund. European solidarity is not an end in itself and should not be a

Read more
20 Feb 2012 08:13

Synchronica signs partnership deal with NewPace

Mobile phone messaging technology group Synchronica has signed a letter of intent with Canada's NewPace Technology Development Inc to cooperate in the development, sales and marketing of a Rich Communication Suite (RCS) product. NewPace will license its current and future RCS technology to bid targ

Read more
15 Feb 2012 07:57

Myriad asks if Synchronica has paid Nokia yet

Swiss mobile devices software firm Myriad, currently mounting a hostile bid for AIM-listed mobile phone messaging technology group Synchronica, has asked the UK group to confirm it has paid the first slug of money it owes to Nokia. On February 14th Synchronica, which bought the messaging business o

Read more
14 Feb 2012 14:45

Synchronica lists myriad reasons to reject Swiss bid

Mobile phone messaging technology group Synchronica has been talking up the prospects of its turnaround plan as it fights off the unwelcome attentions of Swiss mobile devices software firm Myriad. The group said that its cost cutting programme, which it embarked upon late in 2011, will have some ef

Read more
8 Feb 2012 13:16

Synchronica signs letter of intent and unveils JV plans

Mobile phone messaging technology group Synchronica has signed a letter of intent with technology developer Intertainment Media to intergrate Synchronica's messaging platform, Mobile Gateway, with Intertainment Media's Ortsbo experiential language technology. The move has been undertaken in a bid

Read more
18 Jan 2012 16:40

Synchronica signs deal with Chinese firm

Mobile phone messaging technology group Synchronica has signed a $1.5m agreement with a China-based handset manufacturer to bundle Synchronica's Mobile Gateway onto its portfolio of low and ultra-low-cost MediaTek powered handsets. Synchronica anticipates delivery to the customer by the end of Apri

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.